Antibody Oligonucleotide Conjugation
Targeted Oligo DeliveryAOC Design, Conjugation & AnalysisAntibody, Linker and Payload Engineering for Research Programs
Antibody oligonucleotide conjugation combines the target selectivity of antibodies with the functional versatility of oligonucleotide payloads, enabling research teams to build cell-directed siRNA, ASO, PMO, and DNA-barcoded constructs with greater control than non-targeted formats. This service is designed for discovery and research-stage programs that need more than a simple coupling reaction: they need a conjugate architecture that preserves antigen binding, protects payload integrity, and yields interpretable analytical data.
We support custom antibody oligonucleotide conjugation from construct design through purification and characterization, covering full IgG, antibody fragments, and selected engineered formats together with single-stranded and duplex oligonucleotide payloads. Projects may include lysine-, cysteine-, glycan-, or click-enabled routes depending on the target biology, desired oligonucleotide-to-antibody ratio (OAR), and downstream assay requirements. For adjacent needs, our workflows can also connect naturally with antibody conjugation services, oligonucleotide bioconjugation, and broader custom bioconjugation services.
What Problems Does Antibody Oligonucleotide Conjugation Solve?
Many oligonucleotide programs stall not because the payload lacks activity, but because the payload does not reach the right cells in a productive form. Antibody oligonucleotide conjugation addresses this gap by linking a defined oligonucleotide to a target-binding antibody or antibody fragment, allowing teams to study receptor-mediated uptake, cell-selective delivery, and barcode-enabled detection within a single construct. In practice, the value is not just making the bond between two biomolecules; it is generating a conjugate with retained binding, controlled OAR distribution, manageable free-oligo carryover, acceptable aggregate levels, and data that explain how the construct was made and how it behaves.
Real Development Challenges This Service Helps You Address
Uncontrolled OAR and Broad Conjugate Heterogeneity
Random labeling can create wide species distributions that complicate batch comparison and make activity data hard to interpret. We help evaluate conjugation site, handle density, and reaction stoichiometry so the final construct is more defined and analytically traceable.
Loss of Antigen Binding or Payload Function
A successful construct must preserve both sides of the molecule. Steric crowding, over-labeling, or an unsuitable linker can reduce target binding, disrupt duplex integrity, or weaken ASO/PMO performance. Our design approach balances antibody accessibility with oligonucleotide usability.
Difficult Purification of Free Oligo, Free Antibody, and Aggregates
Hybrid biomolecules often require more than one cleanup step. We build purification workflows around the actual impurity profile so unconjugated payload, residual antibody species, and high-molecular-weight material can be reduced before downstream testing.
Incomplete Characterization of a Hybrid Biomolecule
Antibody oligonucleotide conjugates cannot be understood with protein-only or oligo-only analytics alone. We combine orthogonal methods to assess identity, loading, size distribution, site occupancy, and functional retention, giving teams a more reliable basis for candidate selection.
Our Antibody Oligonucleotide Conjugation Services
We provide project-specific support for delivery-oriented and assay-oriented antibody oligonucleotide conjugates, with service design driven by payload class, antibody format, conjugation chemistry, and analytical decision points. When higher orthogonality is required, we can also evaluate routes informed by bioorthogonal reactions and related bioorthogonal click chemistry strategies.
Antibody-siRNA Conjugation
Capabilities include:
- Conjugation route design for duplex siRNA payloads with attention to strand orientation and terminal handle placement
- Screening of stable or trigger-responsive linker options based on uptake and release assumptions
- OAR tuning to reduce over-loading and maintain acceptable antibody behavior
- Purification strategies to separate free siRNA, partially loaded species, and aggregates
- Identity and loading assessment by LC-based and MS-based methods
- Support for targeted knockdown and receptor-mediated uptake studies
Typical project fit:
Cell-selective siRNA delivery constructs, internalization studies, and antibody-guided RNA interference research tools
Antibody-ASO and Antibody-PMO Conjugation
Capabilities include:
- Terminal or site-directed attachment of single-stranded ASO, gapmer, steric-blocking oligo, or PMO payloads
- Conjugation planning to reduce steric interference with target hybridization
- Evaluation of linker length and polarity for construct stability and assay compatibility
- Cleanup workflows for residual free oligo and unconjugated antibody
- Characterization packages tailored to transcript modulation and splice-switching studies
- Batch generation for lead comparison and downstream biological testing
Typical project fit:
Antibody-directed ASO or PMO research constructs for gene modulation, exon-skipping evaluation, and receptor-selective delivery studies
Antibody-DNA Barcode and Detection Probe Conjugation
Capabilities include:
- Conjugation of ssDNA barcodes, hybridization probes, or assay-specific oligonucleotides to antibodies
- Control of barcode copy number to limit assay background and preserve binding performance
- Construct preparation for multiplex immunoassays, proximity assays, and DNA-assisted detection formats
- Orthogonal confirmation of barcode integrity and antibody retention after coupling
- Support for panel generation and multi-construct screening
- Compatibility planning for downstream hybridization workflows
Typical project fit:
DNA-barcoded antibody reagents for protein detection, spatial biology workflows, and highly multiplexed assay development
Linker Selection, Purification & Analytical Characterization
Capabilities include:
- Feasibility review of lysine, cysteine, glycan, and click-enabled conjugation routes
- OAR distribution assessment and species deconvolution
- Quantification of free payload, residual antibody, and high-molecular-weight material
- Intact mass, subunit-level, and site-localization analysis as project needs dictate
- Binding retention, oligo integrity, and stability-oriented evaluation
- Reporting packages that support internal go/no-go decisions and technical transfer
Deliverables:
Conjugation summary, purification outcome, OAR profile, chromatograms, spectra, and structured analytical interpretation for each construct set
Key Design Variables in Antibody Oligonucleotide Conjugation
Construct performance is usually defined by a small number of design choices made early in the project. The table below summarizes the variables that most often determine conjugation homogeneity, biological usability, and analytical complexity.
| Design Parameter | Common Options | What Needs Evaluation | Impact on Final Construct | Project Relevance |
| Antibody Format | Full IgG, Fab, scFv-Fc, or selected engineered fragments | Target affinity, internalization behavior, size, and available conjugation handles | Influences uptake route, tissue accessibility, and ease of downstream analysis | Determines whether the conjugate behaves primarily as a delivery vehicle, a binding reagent, or a barcoded assay tool |
| Oligonucleotide Payload | siRNA, ASO, PMO, ssDNA barcode, or hybridization probe | Strand format, required handle position, duplex stability, and downstream function | Changes purification behavior, linker choice, and assay design | Aligns the conjugate with gene modulation, uptake studies, or detection workflows |
| Antibody Attachment Site | Lysine, native/reduced cysteine, engineered cysteine, glycan-derived handle | Site accessibility, heterogeneity risk, and effect on antibody structure | Strongly affects OAR spread, batch consistency, and binding preservation | One of the most important variables when moving from feasibility to defined constructs |
| Linker Behavior | Stable, reducible, cleavable, or click-installed linker systems | Serum stability, intracellular release assumptions, and process robustness | Shapes payload accessibility, construct stability, and interpretation of biological data | Central to matching chemistry with the intended research question |
| OAR Target Range | Low, moderate, or intentionally higher loading depending on construct purpose | Balance between payload density, antibody integrity, and analytical tractability | Affects potency trends, aggregation tendency, and reproducibility | Essential for comparing construct panels and selecting a workable lead |
| Purification Strategy | SEC, desalting, chromatographic polishing, and orthogonal cleanup steps | Relative amounts of free oligo, free antibody, and higher-order species | Determines usable purity and confidence in subsequent biological readouts | Often decides whether a conjugate is merely made or truly usable |
Conjugation Strategies for Antibody Oligonucleotide Conjugates
No single chemistry is optimal for every antibody oligonucleotide conjugate. Route selection depends on how much positional control is needed, how sensitive the antibody is to modification, and how the final construct will be evaluated biologically and analytically.
| Conjugation Strategy | Technical Approach | Key Strengths | Best-Fit Use Cases |
| Lysine-Directed Conjugation | Reactive ester chemistry installs oligo-bearing or linker-bearing groups onto accessible lysines | Straightforward setup and useful for early feasibility or reagent generation | Exploratory builds where speed matters more than highly defined site control |
| Reduced or Native Cysteine Conjugation | Thiol-reactive chemistry uses exposed or generated cysteine handles on the antibody | Better control than broad lysine labeling and often favorable for defined loading | Constructs requiring tighter OAR distribution with manageable process complexity |
| Engineered Cysteine Conjugation | Site-selected cysteine positions are used for more consistent payload installation | Higher positional definition and easier structure–activity comparisons | Lead constructs where site occupancy and reproducibility are major priorities |
| Glycan-Directed Conjugation | Fc glycan remodeling or glycan-derived handles are used to place the payload away from some native protein surfaces | Can reduce modification of variable regions and support more deliberate positioning | Programs sensitive to binding-region perturbation or seeking Fc-focused installation |
| Bioorthogonal Click Conjugation | Mutually selective handles such as azide/alkyne or tetrazine-based systems enable modular coupling | Orthogonal chemistry, modular build logic, and useful compatibility with pre-functionalized intermediates | Multi-step workflows, payload swapping, or projects needing cleaner selective coupling |
| Enzymatic or Tag-Enabled Installation | Enzyme-recognized tags or site-specific protein modification methods introduce controlled coupling sites | Strong site selectivity with improved comparability between conjugate batches | Advanced projects where process definition matters as much as construct generation |
Analytical Characterization Framework for Antibody Oligonucleotide Conjugation
Because antibody oligonucleotide conjugates combine protein and nucleic acid attributes in one molecule, characterization should address both structural identity and functional usability. A practical analytical framework usually includes orthogonal methods rather than a single release-style readout.
| Analytical Focus | Representative Methods | Question Answered | Typical Output |
| Construct Identity | Intact LC-MS, subunit MS, or mass-confirmation workflows | Was the expected antibody–oligo construct formed? | Molecular weight confirmation and construct assignment |
| OAR and Species Distribution | LC-MS, native MS, chromatographic profiling, and ratio-based evaluation | How many oligonucleotide payloads are attached and how broad is the distribution? | OAR profile, relative abundance of low- and high-load species |
| Free Oligo / Free Antibody Impurities | SEC, ion-exchange, mixed-mode, or other orthogonal separation methods | What residual unconjugated materials remain after cleanup? | Purity assessment and impurity trend overview |
| Aggregation and Fragmentation | SEC-UHPLC, CE-SDS, SDS-PAGE, or equivalent size-based analysis | Has the conjugation process increased high-molecular-weight or fragmented species? | Aggregate level, fragment profile, and lot comparability view |
| Conjugation Site Localization | Subunit mapping, peptide mapping, or site-localization LC-MS workflows | Where is the payload attached and how reproducible is the installation pattern? | Site occupancy interpretation and localization summary |
| Antibody Binding Retention | ELISA, BLI, SPR, or assay-specific binding checks | Does the conjugate still recognize the intended target effectively? | Comparative binding data before and after conjugation |
| Oligo Integrity | Oligo LC, gel-based analysis, duplex verification, or hybridization checks | Has the payload remained intact and functional after coupling and purification? | Payload integrity confirmation and assay suitability assessment |
| Stability Trending | Defined storage studies and stress-oriented follow-up analysis | How stable is the construct during handling, storage, and test workflows? | Stability trend summaries and handling recommendations |
Antibody Oligonucleotide Conjugation Workflow
1. Molecule Review and Project Framing
We review the antibody format, target biology, payload type, available handles, and desired readouts so the project starts with a realistic construct definition instead of a generic coupling plan.
2. Conjugation Route Selection
Candidate chemistries are matched to the molecule pair, with attention to site control, linker behavior, expected OAR, and practical purification consequences.
3. Small-Scale Feasibility and OAR Tuning
Initial reactions are used to confirm construct formation, observe species distribution, and adjust stoichiometry or reaction conditions before committing to a larger build.
4. Purification and Impurity Reduction
Orthogonal cleanup steps are selected based on the observed impurity profile so free oligo, free antibody, salts, and aggregate-related species are reduced efficiently.
5. Structural and Functional Characterization
The conjugate is assessed for identity, OAR, purity, size distribution, payload integrity, and target-binding retention to make the analytical story consistent with the intended use.
6. Batch Delivery and Technical Handoff
Final materials are provided with the agreed analytical package, interpretation notes, and technical recommendations for follow-on screening, scale-up, or construct refinement.
Why Teams Choose Our Antibody Oligonucleotide Conjugation Support
Integrated Antibody and Oligo Chemistry Thinking
We assess the construct as a hybrid biomolecule rather than treating the antibody and oligonucleotide as separate problems, which helps reduce avoidable compatibility issues early.
Practical Control of OAR, Site Choice, and Purity
Our emphasis is on generating a usable construct profile with interpretable loading and manageable impurity levels, not simply maximizing apparent coupling yield.
Orthogonal Characterization for Hybrid Molecules
AOC projects often fail when analytics stop at a single method. We use complementary readouts so identity, heterogeneity, binding retention, and payload integrity can be understood together.
Flexible Support Across Delivery and Assay Builds
We support antibody–siRNA, antibody–ASO, antibody–PMO, and antibody–DNA barcode formats, making it easier to align the conjugation strategy with the real purpose of the project.
Research Applications of Antibody Oligonucleotide Conjugates
Cell-Selective siRNA Delivery Studies
- Evaluation of receptor-guided siRNA uptake using internalizing antibodies or fragments.
- Comparison of linker formats and OAR settings across targeted knockdown constructs.
- Screening of construct panels to identify delivery-efficient designs for further study.
ASO and PMO Delivery Research
- Antibody-directed delivery of splice-switching or transcript-modulating oligonucleotides.
- Construct optimization to preserve hybridization behavior after payload attachment.
- Comparative studies of cell targeting, uptake, and downstream functional readouts.
DNA-Barcoded Antibody Reagents
- Preparation of oligo-tagged antibodies for multiplex protein analysis.
- Support for proximity assays, immuno-PCR-style workflows, and spatial biology tool development.
- Barcode integrity and copy-number control to reduce background and improve assay consistency.
Internalization and Target Validation Platforms
- Side-by-side assessment of antibodies, fragments, or receptor targets as delivery vehicles.
- Build-and-test workflows for understanding how site choice and linker behavior affect uptake.
- Early decision support for selecting a workable construct architecture before deeper investment.
Discuss Your Antibody Oligonucleotide Conjugation Project
Whether you are building a first antibody-oligo feasibility panel, refining a more controlled AOC architecture, or preparing cleaner materials for uptake and functional studies, we provide technically grounded support across construct design, conjugation, purification, and characterization.
Teams typically contact us when they need a workable answer to one or more practical questions: which antibody format to use, where to install the payload, how to control OAR, how to remove free oligo efficiently, or which analytical methods can truly distinguish good constructs from confusing ones.Contact our scientific team to discuss your target, antibody format, oligonucleotide payload, and desired analytical endpoints.
Frequently Asked Questions (FAQ)
What is antibody-oligonucleotide conjugation?
Antibody-oligonucleotide conjugation is the process of chemically or enzymatically linking DNA or RNA fragments to antibodies. This allows researchers to combine the targeting specificity of antibodies with the information-carrying capacity of nucleic acids for molecular detection or assay development.
What strategies are used to control oligonucleotide orientation on the antibody?
Orientation can be managed using site-specific attachment points, engineered tags, or linker chemistry. Proper orientation ensures predictable hybridization and minimizes steric hindrance during molecular recognition.
Which analytical techniques are suitable for characterizing antibody-oligonucleotide conjugates?
Techniques like SDS-PAGE with fluorescent detection, capillary electrophoresis, and mass spectrometry allow assessment of conjugation efficiency, oligonucleotide load, and structural integrity without relying on functional assays.
